Melissa Triebell

Executive Director, Portfolio & Programs Management at Biosplice Therapeutics - San Diego, CA, us

Melissa Triebell's Contact Details
HQ
N/A
Location
San Diego,California,United States
Company
Biosplice Therapeutics
Melissa Triebell's Company Details
Biosplice Therapeutics logo, Biosplice Therapeutics contact details

Biosplice Therapeutics

San Diego, CA, us • 100 - 249 Employees
BioTech/Drugs

Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice's target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular "command and control" center.Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to other degenerative conditions. Learn more at https://www.biosplice.com

Biotechnology
Details about Biosplice Therapeutics
Frequently Asked Questions about Melissa Triebell
Melissa Triebell currently works for Biosplice Therapeutics.
Melissa Triebell's role at Biosplice Therapeutics is Executive Director, Portfolio & Programs Management.
Melissa Triebell's email address is ***@samumed.com. To view Melissa Triebell's full email address, please signup to ConnectPlex.
Melissa Triebell works in the Research industry.
Melissa Triebell's colleagues at Biosplice Therapeutics are Christopher Swearingen, Emily Creger, Heli Ghandehari, Melinda Pedraza, Paula Sepeda, Labed Dabbagh, Alyna Lam and others.
Melissa Triebell's phone number is N/A
See more information about Melissa Triebell